← Back to Search

Potassium Channel Blocker

4-Aminopyridine for Nerve Injury

Phase 2 & 3
Waitlist Available
Led By John C Elfar, MD
Research Sponsored by Milton S. Hershey Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during dosing of drug intervention (5 hours) and 2, 6, 9, 12, 15, 20 weeks post injury
Awards & highlights

Study Summary

This trial will test whether 4-aminopyridine can speed up the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during dosing of drug intervention (5 hours) and 2, 6, 9, 12, 15, 20 weeks post injury
This trial's timeline: 3 weeks for screening, Varies for treatment, and during dosing of drug intervention (5 hours) and 2, 6, 9, 12, 15, 20 weeks post injury for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subjective Return of Sensation

Side effects data

From 2013 Phase 4 trial • 901 Patients • NCT01480076
12%
Insomnia
10%
Headache
9%
Multiple Sclerosis Relapse
8%
Urinary Tract Infection
8%
Nasopharyngitis
8%
Nausea
7%
Fall
5%
Dizziness
4%
Fatigue
100%
80%
60%
40%
20%
0%
Study treatment Arm
Responder
All Participants
Non-responder

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single dose 4APExperimental Treatment1 Intervention
15mm opaque capsule containing 10mg of 4-AP
Group II: PlaceboPlacebo Group1 Intervention
Opaque capsule identical looking to the 4AP placebo pill

Find a Location

Who is running the clinical trial?

Milton S. Hershey Medical CenterLead Sponsor
495 Previous Clinical Trials
2,798,873 Total Patients Enrolled
1 Trials studying Nerve Injury
70 Patients Enrolled for Nerve Injury
John C Elfar, MDPrincipal InvestigatorMilton S. Hershey Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The LancetJournal
Dried Blood Spot Technology for CD4+ T-cell Counting
Shapiro, Howard M, Francis F Mandy, Paul Sandstrom, and Tobias F Rinke de Wit. 2004. “Dried Blood Spot Technology for CD4+ T-cell Counting”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(03)15270-1.
The LancetJournal
Dried Blood Spot Technology for CD4+ T-cell Counting
Shapiro, Howard M, Francis F Mandy, Paul Sandstrom, and Tobias F Rinke de Wit. 2004. “Dried Blood Spot Technology for CD4+ T-cell Counting”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(03)15270-1.
clinicaltrials.govStudy
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma
John Elfar 2021. "A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04026568.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top